Status | Study |
Recruiting |
Study Name: Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Condition: Germ Cell Tumor Nonseminomatous Germ Cell Tumor Date: 2017-05-16 Interventions: Drug: Durvalumab 1500 mg by IV |
Recruiting |
Study Name: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Condition: Acinar Cell Carcinoma Adrenal Cortex Carcinoma Adrenal Gla Date: 2016-07-13 Interventions: Procedure: Biospecimen Collection |
Recruiting |
Study Name: Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Condition: Germ Cell Tumors Testis Cancer Testicular Cancer Date: 2016-02-12 Interventions: Drug: Brentuximab Vedotin Both cohorts will be treated similarly and in parallel but analyzed separately |
Active, not recruiting |
Study Name: Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors Condition: Germ Cell Neoplasms Testicular Neoplasms Date: 2015-07-08 Interventions: Drug: Pembrolizumab 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 |
Recruiting |
Study Name: First Line TIP in Poor Prognosis TGCTs. Condition: Germ Cell Tumor Date: 2015-04-08 Interventions: Drug: Paclitaxel paclitaxel, i |
Recruiting |
Study Name: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Condition: Germ Cell Tumor Teratoma Choriocarcinoma Date: 2015-02-20 Interventions: Drug: paclitaxel IV |
Recruiting |
Study Name: Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy Condition: Non-seminomatous Germ Cell Tumors Metastasis Date: 2014-08-25 Interventions: Other: K5-RGD PET Both PET exa |
Recruiting |
Study Name: A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors Condition: Non-seminomatous Germ-cell Tumors Date: 2014-04-10 Interventions: Drug: Cabazitaxel On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², |
Terminated |
Study Name: Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors Condition: Adult Central Nervous System Germ Cell Tumor Adult Teratoma Date: 2013-03-06 Interventions: Drug: palifosfamide Given IV Other Names: |
Active, not recruiting |
Study Name: Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours Condition: Stage I Testicular Non-Seminomatous Germ Cell Tumor Date: 2012-11-09 Interventions: Drug: BEP(500) One cycle of BEP(500): |